The gene synthesis industry is undergoing a fundamental shift in how genetic constructs are conceived, designed, and manufactured. Where researchers once relied on iterative laboratory experimentation to optimize sequences, AI models are now performing that work computationally - predicting synthesis failures, generating novel regulatory elements, and designing gene editors that do not exist in nature. The result is a field that is moving faster, producing more accurate outputs, and addressing therapeutic challenges that were previously intractable.
Because this is a pulse and qualitative report rather than a traditionally sized market study, the most telling indicators of momentum are investment flows and adoption rates. Venture capital directed at AI businesses grew from roughly $3 billion in 2012 to $75 billion in 2020, with approximately 20% of all VC investment in 2020 going toward AI-related projects. By 2024, corporate AI investment globally reached $252.3 billion - more than thirteenfold growth since 2014. In the same year, the proportion of businesses using AI in at least one function rose from 55% to 78%, and adoption of generative AI specifically jumped from 33% to 71%. These numbers reflect a structural change in how the biotechnology sector operates, not a temporary experiment.
Within gene synthesis specifically, the capital is flowing toward companies building foundation models and automated platforms that can handle the full design-to-synthesis pipeline. Generate Biomedicines raised $400 million in a 2026 IPO to expand AI-driven protein therapeutic design. Profluent closed a $106 million round in 2025, bringing its total funding to approximately $150 million, to accelerate AI-designed genome editors and biomanufacturing applications. Six distinct technology categories are driving this transformation, each reshaping a different layer of gene synthesis work.
Large language models trained on vast biological datasets of DNA sequences and protein structures can generate entirely new CRISPR-like proteins and gene-editing systems that have no natural counterpart. Profluent's OpenCRISPR-1 is the most prominent example - an LLM-designed gene editor that achieves a median rate of undesired genetic alterations below 1% while incorporating over 400 mutations compared to conventional CRISPR. This approach moves gene editor design from a discovery science into an engineering discipline.
• AI-designed genome editors such as OpenCRISPR-1 for precision gene therapy in complex genetic disorders
• Design of AI-engineered antibodies and enzymes for biomanufacturing applications
• Development of novel CRISPR-like proteins for therapeutic use where natural proteins fall short
• AI-powered diagnostics and molecular probe design
• Accurate on-target prediction in CRISPR/Cas9 gene editing to reduce unintended modifications
Diffusion models such as DNA-Diffusion, developed by researchers at the Broad Institute and Mass General Brigham, are trained on chromatin accessibility data to generate synthetic cis-regulatory elements (CREs) that control gene expression in specific cell types. Rather than repurposing naturally occurring regulatory sequences with limited specificity, these models can produce synthetic enhancers and promoters engineered from the ground up to activate therapeutic genes only where needed. AI-generated regulatory sequences have been shown to outperform natural elements in both specificity and efficiency.
• Cell-type-specific gene expression control in gene therapy, including AXIN2 activation in B cells for chronic lymphocytic leukaemia
• Integration of synthetic regulatory elements into AAV-based gene delivery systems
• Design of synthetic enhancers and promoters for synthetic biology applications
• Precision targeting in genome-editing technologies requiring cell-type restriction
• Generation of over 5,800 synthetic CREs for experimental validation, demonstrating production scale
A broad suite of deep learning architectures - including convolutional neural networks, recurrent neural networks, LSTMs, Transformers, and attention mechanisms - are deployed in tools such as DeepCpf1, CRISPRLearner, DeepHF, SeqCrispr, and OpenCRISPR-1 to predict and optimize guide RNA on-target efficiency and off-target activity. These models take the computational burden of sgRNA design and convert what was once a slow, expensive laboratory process into a rapid in silico workflow, with direct consequences for the safety and reliability of clinical-grade gene therapies.
• On-target efficiency prediction for CRISPR/Cas9 single guide RNA design
• Off-target activity prediction for base editors, including ABEdeepoff and CBEdeepoff
• Prediction of sgRNA specificity across multiple Cas protein systems including Cas9, Cas13, and Cpf1
• Editing outcome prediction for prime editing via DeepPE and base editing via BE-Hive
• Large-scale functional genomics screening across entire gene sets
Machine learning algorithms integrated directly into automated DNA synthesis platforms monitor synthesis reactions in real time, adjust process variables, and forecast failures caused by difficult sequence features such as high GC content, repetitive regions, and complex secondary structures. These systems detect faulty constructs before they reach the customer, replacing post-synthesis testing as the primary quality gate with continuous in-process monitoring. The effect on throughput and yield can be substantial, particularly for contract research organizations operating at volume.
• Real-time synthesis reaction monitoring and dynamic process adjustment during manufacturing
• Prediction and prevention of synthesis failures from GC-rich or repetitive sequence regions
• Automated sequencing data analysis and mutation detection for quality assurance before product delivery
• Codon optimization for synthetic gene design in biopharmaceutical manufacturing
• Workflow automation for contract research organizations to increase throughput and reduce labor costs
Foundation models and large language models trained on biological sequences - covering DNA, RNA, and protein - enable the computational generation of entirely new genes, proteins, and regulatory elements. Rather than selecting from known biological parts, researchers can use these models to screen vast numbers of candidate sequences in silico before committing to any laboratory synthesis. Generate Biomedicines, which raised $400 million in its 2026 IPO, is built around precisely this capability: applying foundation models to design protein therapeutics at scale.
• Design of novel protein therapeutics and deployment of computational biology platforms for drug discovery
• AI-driven discovery of new Cas protein families for gene editing beyond currently characterized systems
• Generation of synthetic enzymes with improved performance characteristics for industrial applications
• Design of metabolic pathways and genetic circuits for industrial biotechnology including biofuels and specialty chemicals
• Development of mRNA-based drugs and next-generation vaccines through large-scale sequence generation and screening
AI-driven models - including protein language models and deep learning-based predictors - enhance CRISPR-Cas systems by enabling more precise sgRNA design, identifying new Cas protein families, and improving gene regulatory network analysis at a scale that manual approaches cannot match. This layer of AI integration is where computational advances translate most directly into clinical outcomes, enabling therapeutic genome editing for conditions that conventional CRISPR approaches struggled to address safely. The combination of large-scale data integration and reduced off-target effects is what makes this category central to the next generation of gene therapies.
• Therapeutic genome editing for complex and previously difficult-to-treat genetic disorders
• Functional genomics research conducted at scale with AI-assisted data interpretation
• Design of CAR-T and gene therapy constructs with improved targeting accuracy
• Optimization of CRISPR delivery systems including AAV-based vectors
• Development of safer, more accurate gene therapies aligned with precision medicine objectives
Among adopter segments, biotechnology and pharmaceutical companies represent the largest and most advanced users of AI in gene synthesis, applying AI platforms to synthetic gene design, therapeutic development, and protein engineering at moderate to high adoption levels. Contract research organizations (CROs) also operate at moderate to high adoption, using AI specifically for sequence optimization, error prediction, and workflow automation - areas where throughput improvements translate directly into commercial advantage. Academic and government research institutes remain at lower adoption levels, contributing to generative DNA design, genomics, and synthetic biology research but constrained by infrastructure and funding relative to commercial players.
Regionally, North America leads implementation across AI, machine learning, and computational technologies in gene synthesis, supported by established research infrastructure, a stable funding environment, and the presence of major organizations including Thermo Fisher Scientific, Twist Bioscience, and GenScript. The U.S. alone attracted $109.1 billion in private AI investment in 2024. Asia-Pacific is the fastest-growing region, with China having established 17 biomedical clusters across major cities and surpassing Europe in AI scientific publications, while India attracted $1.4 billion in private AI investment in 2023. Europe is actively promoting AI-first strategies in gene therapy but faces a more complex regulatory environment due to the EU AI Act's strict risk-classification requirements for healthcare applications, which is slowing adoption relative to the U.S. The rest of the world - including Latin America, the Middle East, and Africa - remains in early-stage adoption, with Brazil, Mexico, the UAE, and Saudi Arabia making initial investments in AI for healthcare, vaccine discovery, and vector design.
The six technologies covered here - generative AI and LLMs for gene editing, diffusion-based models for synthetic regulatory elements, deep learning for guide RNA optimization, automated synthesis and quality control platforms, protein and foundation models for sequence design, and AI integration with CRISPR systems - are not isolated research tools. They are forming an interconnected infrastructure that is changing what gene synthesis can produce and how quickly it can produce it. The consistent investment signals, from billion-dollar corporate allocations to targeted venture rounds in companies such as Profluent and Generate Biomedicines, indicate that this infrastructure is being built with commercial application in mind, not basic science alone.
Over the coming years, the competitive divide between organizations that have embedded AI across the synthesis workflow and those still relying on conventional experimental iteration will widen. Therapeutic programs in mRNA drugs, CAR-T therapies, and AAV-delivered gene therapies will increasingly depend on AI-designed genetic constructs to meet the specificity and safety requirements that regulators and clinicians require. For industry professionals and analysts tracking this space, the primary question is no longer whether AI will reshape gene synthesis - the investment data and technical results confirm that it already is - but which organizations are building the computational foundations that will define the field's next decade.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.